Zobrazeno 1 - 10
of 262
pro vyhledávání: '"Miguel A. Villalona Calero"'
Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors
Autor:
Miguel A. Villalona-Calero, John P. Diaz, Wenrui Duan, Zuanel Diaz, Eric D. Schroeder, Santiago Aparo, Troy Gatcliffe, Federico Albrecht, Siddhartha Venkatappa, Victor Guardiola, Sara Garrido, Muni Rubens, Fernando DeZarraga, Hao Vuong
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-11 (2022)
Abstract Background Given the observed antitumor activity of immune-checkpoint-inhibitors in patients with mismatch-repair deficient (MSI-H) tumors, we hypothesized that deficiency in homologous-recombination-repair (HRR) can also influence susceptib
Externí odkaz:
https://doaj.org/article/638687a2c44a4b188f5880b1264f5ad8
Autor:
Oliver H. Voss, Daniel Arango, Justin C. Tossey, Miguel A. Villalona Calero, Andrea I. Doseff
Publikováno v:
Cell Death and Disease, Vol 12, Iss 4, Pp 1-12 (2021)
Abstract Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selective killing of cancer cells underlines its anticancer potential. However, poor tolerability and resistance underscores the need to identify cancer-selective TRAIL-sensitiz
Externí odkaz:
https://doaj.org/article/f396aaa397634230b2ad7b3fbf1922c9
Autor:
Wenrui Duan, Shirley Tang, Li Gao, Kathleen Dotts, Andrew Fink, Arjun Kalvala, Brittany Aguila, Qi-En Wang, Miguel A. Villalona-Calero
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract The Fanconi Anemia (FA) pathway is essential for human cells to maintain genomic integrity following DNA damage. This pathway is involved in repairing damaged DNA through homologous recombination. Cancers with a defective FA pathway are expe
Externí odkaz:
https://doaj.org/article/00e5274edafd4aabbc69514504bfd27d
Autor:
Julian Ramelow, Christopher D. Brooks, Li Gao, Abeer A. Almiman, Terence M. Williams, Miguel A. Villalona-Calero, Wenrui Duan
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Lung cancer is the number one cancer killer worldwide. A major drawback in the lung cancer treatment field is the lack of realistic mouse models that replicate the complexity of human malignancy and immune contexture within the tu
Externí odkaz:
https://doaj.org/article/7d3855f9e97a42afa2bc6c08c7a8c23b
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Investigator-assessed best confirmed response to treatment with pazopanib and paclitaxel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9672b7ca2c278dae175f8f306ff555de
https://doi.org/10.1158/1535-7163.22502157.v1
https://doi.org/10.1158/1535-7163.22502157.v1
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Drug exposure for paclitaxel and pazopanib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0615d6fc6e040bc2461b00680e30c9f3
https://doi.org/10.1158/1535-7163.22502163
https://doi.org/10.1158/1535-7163.22502163
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Liver function tests for a cohort 1 patient with a hepatotoxicity dose-limiting toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9c97eef3b4beb738ce9fbeba6e7dd48
https://doi.org/10.1158/1535-7163.22502169.v1
https://doi.org/10.1158/1535-7163.22502169.v1
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Pharmacokinetic data for a cohort 1 patient with hepatotoxicity dose-limiting toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5cad2f0eaad56561c1dac53fb27a36
https://doi.org/10.1158/1535-7163.22502166
https://doi.org/10.1158/1535-7163.22502166
Autor:
Miguel A. Villalona-Calero, Lone H. Ottesen, Chun-Fang Xu, Natalie Compton, A. Benjamin Suttle, Elaine M. Paul, Mary E. R. O'Brien, Ravi Salgia, Ruth Plummer, Kari L. Kendra
Summary of paclitaxel pharmacokinetic parameters
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bad83740a4222a581b1c5e31ac9d0f38
https://doi.org/10.1158/1535-7163.22502160
https://doi.org/10.1158/1535-7163.22502160
Autor:
James H. Doroshow, Richard M. Simon, Barbara A. Conley, Robert J. Kinders, P. Mickey Williams, Seth M. Steinberg, Paul M. McGregor, William D. Walsh, Michele G. Mehaffey, Chih-Jian Lih, Deborah E. Allen, Jiuping Ji, Alice P. Chen, Ahrim Youn, Peter M. Szabo, Robert J. Morgan, Miguel A. Villalona-Calero, Michael J. Naughton, David R. Gandara, Daniel M. Sullivan, Gini F. Fleming, Amit M. Oza, Shivaani Kummar
Supplemental Figure S1. Kaplan-Meier analysis of the progression free survival (PFS) of patients on each treatment arm stratified by BRCA status showed no significant differences.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac78b660c4e98ad73ca9863a9f1c1ebb
https://doi.org/10.1158/1078-0432.22461263.v1
https://doi.org/10.1158/1078-0432.22461263.v1